MedTrace Logo

CapeOx Combined With Anti-PD1 Antibody Plus Dihydroartemisinin as Neoadjuvant or Conversion Therapy for Microsatellite Stable Locally Advanced and Metastatic Colorectal Cancer

NCT07801352 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-09-03

No results posted yet for this study

Summary

This prospective, single-arm study aims to investigate the efficacy and safety of CapeOX combined with anti-PD1 antibody plus dihydroartemisinin as neoadjuvant or conversion therapy for pMMR/MSS locally advanced and metastatic colorectal cancer

Conditions

Interventions

DRUG

Capecitabine

Capecitabine is given orally at 1000mg / m² twice a day from day1-14 every 3 weeks for 4 cycles

DRUG

Oxaliplatin

Oxaliplatin is given by intravenous infusion at 130mg / m2 on Day 1 every 3 weeks for 4 cycles

DRUG

Dihydroartemisinin

For locally advanced colorectal cancer, dihydroartemisinin is given orally at 20mg three times a day from day1-21 every 3 weeks for 2 cycles from the third cycle; for metastatic colorectal cancer, dihydroartemisinin is given orally at 20mg three times a day from day1-21 every 3 weeks for 4 cycles.

DRUG

Tislelizumab

Tislelizumab is given intravenously at 200 mg on day 1 every 3 weeks for 4 cycles

Sponsors & Collaborators

  • Shanghai Changzheng Hospital

    lead OTHER

Principal Investigators

  • Haiyang Zhou, MD · Shanghai Changzheng Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2025-07-28
Completion
2028-04-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07801352 on ClinicalTrials.gov